NasdaqCM - Nasdaq Real Time Price USD

Bright Minds Biosciences Inc. (DRUG)

Compare
46.80 -0.59 (-1.24%)
At close: October 31 at 4:00 PM EDT
47.49 +0.69 (+1.47%)
After hours: October 31 at 7:59 PM EDT
Loading Chart for DRUG
DELL
  • Previous Close 47.39
  • Open 46.75
  • Bid 45.60 x 100
  • Ask 46.97 x 400
  • Day's Range 45.50 - 50.25
  • 52 Week Range 0.93 - 79.02
  • Volume 395,699
  • Avg. Volume 2,988,695
  • Market Cap (intraday) 218.042M
  • Beta (5Y Monthly) 1.73
  • PE Ratio (TTM) --
  • EPS (TTM) -0.63
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

brightmindsbio.com

--

Full Time Employees

September 30

Fiscal Year Ends

Recent News: DRUG

View More

Performance Overview: DRUG

Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DRUG
3,172.73%
S&P/TSX Composite index
15.26%

1-Year Return

DRUG
3,418.80%
S&P/TSX Composite index
28.11%

3-Year Return

DRUG
31.46%
S&P/TSX Composite index
14.83%

5-Year Return

DRUG
78.80%
S&P/TSX Composite index
28.39%

Compare To: DRUG

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DRUG

View More

Valuation Measures

Annual
As of 10/30/2024
  • Market Cap

    214.43M

  • Enterprise Value

    209.99M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    48.18

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -28.86%

  • Return on Equity (ttm)

    -51.80%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -3.58M

  • Diluted EPS (ttm)

    -0.63

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.19M

  • Total Debt/Equity (mrq)

    0.23%

  • Levered Free Cash Flow (ttm)

    -1.34M

Research Analysis: DRUG

View More

Company Insights: DRUG

Research Reports: DRUG

View More

People Also Watch